Allegro was founded in 2021 with the ultimate vision to augment humanity and prolong life, engineering the body atom-by-atom, blending nanotech and biotech. The company developed a promising nanotechnology platform to build therapeutic nanoparticles for orthopaedics, neuroscience, and chronic degenerative diseases. Allegro brings Xyletra to the market, the world's first disease-modifying treatment for osteoarthritis, which stops the degenerative process and alleviates pain with a year-long effect on a single shot administration.